Tianda Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Tianda Pharmaceuticals's earnings have been declining at an average annual rate of -53.9%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 1.1% per year.
Key information
-53.9%
Earnings growth rate
-53.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 1.1% |
| Return on equity | -4.2% |
| Net Margin | -4.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?
Jun 20
There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump
Mar 27Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)
Mar 02Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?
May 23Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?
Dec 06Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Jan 11Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?
Aug 05Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?
Dec 11Revenue & Expenses Breakdown
How Tianda Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 532 | -24 | 271 | 13 |
| 31 Dec 22 | 547 | -55 | 286 | 36 |
| 30 Sep 22 | 523 | -18 | 276 | 25 |
| 30 Jun 22 | 517 | -19 | 273 | 20 |
| 31 Mar 22 | 510 | -20 | 269 | 16 |
| 31 Dec 21 | 517 | -25 | 270 | 12 |
| 30 Sep 21 | 523 | -30 | 270 | 8 |
| 30 Jun 21 | 499 | -28 | 276 | 10 |
| 31 Mar 21 | 474 | -27 | 282 | 12 |
| 31 Dec 20 | 445 | -21 | 285 | 10 |
| 30 Sep 20 | 417 | -15 | 289 | 8 |
| 30 Jun 20 | 454 | -6 | 320 | 5 |
| 31 Mar 20 | 491 | 3 | 350 | 2 |
| 31 Dec 19 | 507 | 3 | 374 | 4 |
| 30 Sep 19 | 523 | 3 | 398 | 7 |
| 30 Jun 19 | 525 | 3 | 403 | 7 |
| 31 Mar 19 | 527 | 3 | 408 | 7 |
| 31 Dec 18 | 514 | 6 | 397 | 5 |
| 30 Sep 18 | 501 | 10 | 386 | 3 |
| 30 Jun 18 | 431 | 10 | 319 | 3 |
| 31 Mar 18 | 362 | 10 | 252 | 3 |
| 31 Dec 17 | 295 | 7 | 189 | 3 |
| 30 Sep 17 | 228 | 4 | 125 | 3 |
| 30 Jun 17 | 212 | 8 | 112 | 3 |
| 31 Mar 17 | 196 | 12 | 100 | 3 |
| 31 Dec 16 | 190 | 14 | 99 | 2 |
| 30 Sep 16 | 184 | 15 | 99 | 0 |
| 30 Jun 16 | 188 | 11 | 100 | 1 |
| 31 Mar 16 | 193 | 7 | 101 | 1 |
| 31 Dec 15 | 184 | 0 | 102 | 1 |
| 30 Sep 15 | 175 | -6 | 103 | 2 |
| 30 Jun 15 | 157 | -12 | 103 | 2 |
| 31 Mar 15 | 139 | -18 | 103 | 2 |
| 31 Dec 14 | 164 | -10 | 106 | 2 |
| 30 Sep 14 | 189 | -3 | 108 | 2 |
| 30 Jun 14 | 218 | 10 | 104 | 2 |
| 31 Mar 14 | 247 | 22 | 99 | 2 |
| 31 Dec 13 | 242 | 26 | 94 | 2 |
| 30 Sep 13 | 237 | 29 | 89 | 3 |
| 30 Jun 13 | 209 | 27 | 79 | 2 |
Quality Earnings: 455 is currently unprofitable.
Growing Profit Margin: 455 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 455 is unprofitable, and losses have increased over the past 5 years at a rate of 53.9% per year.
Accelerating Growth: Unable to compare 455's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 455 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.3%).
Return on Equity
High ROE: 455 has a negative Return on Equity (-4.22%), as it is currently unprofitable.